{"id":19985,"date":"2014-04-22T07:31:22","date_gmt":"2014-04-22T11:31:22","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=19985"},"modified":"2014-04-22T07:31:22","modified_gmt":"2014-04-22T11:31:22","slug":"rexahn-pharmaceuticals-inc-nysemktrnn-pioneering-research-in-oncology","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/rexahn-pharmaceuticals-inc-nysemktrnn-pioneering-research-in-oncology-19985","title":{"rendered":"Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN): Pioneering Research In Oncology"},"content":{"rendered":"<p style=\"text-align: justify;\">Boston, MA 04\/22\/2014 (wallstreetpr) &#8211;\u00a0<b>Rexahn Pharmaceuticals, Inc. <\/b><b>(NYSEMKT:RNN) <\/b>focuses largely on cancer research.<\/p>\n<p style=\"text-align: justify;\"><b>Innovations and Research<\/b><\/p>\n<p style=\"text-align: justify;\">The company has witnessed promising preclinical results for RX-21101, its first development candidate obtained from its Nano-Polymer-Drug Conjugate System (NPDCS) platform.\u00a0 RX-21101 has showed enhanced tumor regression, complete tumor growth inhibition and extended survival in xenograft models.<\/p>\n<p style=\"text-align: justify;\">Rexahn Pharmaceuticals Inc has come up with the initial data for the First Phase dose increment clinical trial of a new drug, Supinoxin(TM)(RX-5902). This research is still going on, and achievement of maximal tolerated dose (MTD) is still awaited. Three dosing cycles of 25, 50 and 100 mg have been completed so far. Not a single drug related adverse event has been reported so far. The fourth cycle of 150 mg dose has been initiated.<\/p>\n<p style=\"text-align: justify;\">The company has initiated a Phase Ib clinical trial to study in depth the safety and efficacy of RX-3117 in patients suffering from cancer and having solid tumors. This trial is a dose escalation study which is being done to evaluate the tolerability, safety and maximal tolerated dose (MTD) of this drug in such patients.<\/p>\n<p style=\"text-align: justify;\">Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) has been granted a patent, EP 1546180 by the European Patent Office for its clinical development molecule Archexin. It finds use in inhibiting the activated form of Akt-1 (phospho-Akt1) for cancer treatment. Initiation of Phase II clinical trial to study the safety and efficacy of the drug in patients suffering from metastatic renal cell carcinoma (RCC) has been done. Archexin had earlier been granted Orphan Drug Designation for RCC indication. Top line results from Phase 2 study of Archexin have been announced by the company.<\/p>\n<p style=\"text-align: justify;\">Some institutional investors have expressed an interest to buy $5.3 million of Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN)\u2019s securities. Rexahn went into a securities purchase contract with these investors. Following this deal, Rexahn has agreed to sell off 10.2 million shares of its common stock.<\/p>\n<p style=\"text-align: justify;\">U.S. Patent and Trademark Office has issued patent for quinazoline compounds, method for producing antitumor effect and their composition.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Boston, MA 04\/22\/2014 (wallstreetpr) &#8211;\u00a0Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) focuses largely on cancer research. Innovations and Research The company has witnessed promising preclinical results for RX-21101, [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":13605,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[4343,4342],"stock_ticker":[],"class_list":["post-19985","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-nysemktrnn","tag-rexahn-pharmaceuticals-inc-nysemktrnn","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN): Pioneering Research In Oncology  - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/rexahn-pharmaceuticals-inc-nysemktrnn-pioneering-research-in-oncology-19985\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN): Pioneering Research In Oncology  - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Boston, MA 04\/22\/2014 (wallstreetpr) &#8211;\u00a0Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) focuses largely on cancer research. Innovations and Research The company has witnessed promising preclinical results for RX-21101, [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/rexahn-pharmaceuticals-inc-nysemktrnn-pioneering-research-in-oncology-19985\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2014-04-22T11:31:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/01\/Rexahn-Pharmaceuticals.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"335\" \/>\n\t<meta property=\"og:image:height\" content=\"116\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fiona Gibson\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fiona Gibson\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/rexahn-pharmaceuticals-inc-nysemktrnn-pioneering-research-in-oncology-19985#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/rexahn-pharmaceuticals-inc-nysemktrnn-pioneering-research-in-oncology-19985\"},\"author\":{\"name\":\"Fiona Gibson\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e5ef7ff4b449e42e0b2e812283dba24e\"},\"headline\":\"Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN): Pioneering Research In Oncology\",\"datePublished\":\"2014-04-22T11:31:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/rexahn-pharmaceuticals-inc-nysemktrnn-pioneering-research-in-oncology-19985\"},\"wordCount\":342,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/rexahn-pharmaceuticals-inc-nysemktrnn-pioneering-research-in-oncology-19985#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/01\/Rexahn-Pharmaceuticals.jpg\",\"keywords\":[\"NYSEMKT:RNN\",\"Rexahn Pharmaceuticals Inc. (NYSEMKT:RNN)\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/rexahn-pharmaceuticals-inc-nysemktrnn-pioneering-research-in-oncology-19985#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/rexahn-pharmaceuticals-inc-nysemktrnn-pioneering-research-in-oncology-19985\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/rexahn-pharmaceuticals-inc-nysemktrnn-pioneering-research-in-oncology-19985\",\"name\":\"Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN): Pioneering Research In Oncology - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/rexahn-pharmaceuticals-inc-nysemktrnn-pioneering-research-in-oncology-19985#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/rexahn-pharmaceuticals-inc-nysemktrnn-pioneering-research-in-oncology-19985#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/01\/Rexahn-Pharmaceuticals.jpg\",\"datePublished\":\"2014-04-22T11:31:22+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/rexahn-pharmaceuticals-inc-nysemktrnn-pioneering-research-in-oncology-19985#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/rexahn-pharmaceuticals-inc-nysemktrnn-pioneering-research-in-oncology-19985\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/rexahn-pharmaceuticals-inc-nysemktrnn-pioneering-research-in-oncology-19985#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/01\/Rexahn-Pharmaceuticals.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/01\/Rexahn-Pharmaceuticals.jpg\",\"width\":335,\"height\":116},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/rexahn-pharmaceuticals-inc-nysemktrnn-pioneering-research-in-oncology-19985#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN): Pioneering Research In Oncology\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e5ef7ff4b449e42e0b2e812283dba24e\",\"name\":\"Fiona Gibson\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f92ca1ce6ecdb59f7bac42afaacd292b.jpeg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f92ca1ce6ecdb59f7bac42afaacd292b.jpeg\",\"caption\":\"Fiona Gibson\"},\"description\":\"Fiona is a finance graduate and an expert in analyzing market trends.\",\"sameAs\":[\"https:\/\/cablemanpro.com\/wallstreetpr\",\"https:\/\/x.com\/@fionahime\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/fiona-gibson\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN): Pioneering Research In Oncology  - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/rexahn-pharmaceuticals-inc-nysemktrnn-pioneering-research-in-oncology-19985","og_locale":"en_US","og_type":"article","og_title":"Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN): Pioneering Research In Oncology  - Wall Street PR","og_description":"Boston, MA 04\/22\/2014 (wallstreetpr) &#8211;\u00a0Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) focuses largely on cancer research. Innovations and Research The company has witnessed promising preclinical results for RX-21101, [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/rexahn-pharmaceuticals-inc-nysemktrnn-pioneering-research-in-oncology-19985","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2014-04-22T11:31:22+00:00","og_image":[{"width":335,"height":116,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/01\/Rexahn-Pharmaceuticals.jpg","type":"image\/jpeg"}],"author":"Fiona Gibson","twitter_misc":{"Written by":"Fiona Gibson","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/rexahn-pharmaceuticals-inc-nysemktrnn-pioneering-research-in-oncology-19985#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/rexahn-pharmaceuticals-inc-nysemktrnn-pioneering-research-in-oncology-19985"},"author":{"name":"Fiona Gibson","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e5ef7ff4b449e42e0b2e812283dba24e"},"headline":"Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN): Pioneering Research In Oncology","datePublished":"2014-04-22T11:31:22+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/rexahn-pharmaceuticals-inc-nysemktrnn-pioneering-research-in-oncology-19985"},"wordCount":342,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/rexahn-pharmaceuticals-inc-nysemktrnn-pioneering-research-in-oncology-19985#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/01\/Rexahn-Pharmaceuticals.jpg","keywords":["NYSEMKT:RNN","Rexahn Pharmaceuticals Inc. (NYSEMKT:RNN)"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/rexahn-pharmaceuticals-inc-nysemktrnn-pioneering-research-in-oncology-19985#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/rexahn-pharmaceuticals-inc-nysemktrnn-pioneering-research-in-oncology-19985","url":"https:\/\/cablemanpro.com\/wallstreetpr\/rexahn-pharmaceuticals-inc-nysemktrnn-pioneering-research-in-oncology-19985","name":"Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN): Pioneering Research In Oncology - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/rexahn-pharmaceuticals-inc-nysemktrnn-pioneering-research-in-oncology-19985#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/rexahn-pharmaceuticals-inc-nysemktrnn-pioneering-research-in-oncology-19985#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/01\/Rexahn-Pharmaceuticals.jpg","datePublished":"2014-04-22T11:31:22+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/rexahn-pharmaceuticals-inc-nysemktrnn-pioneering-research-in-oncology-19985#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/rexahn-pharmaceuticals-inc-nysemktrnn-pioneering-research-in-oncology-19985"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/rexahn-pharmaceuticals-inc-nysemktrnn-pioneering-research-in-oncology-19985#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/01\/Rexahn-Pharmaceuticals.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/01\/Rexahn-Pharmaceuticals.jpg","width":335,"height":116},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/rexahn-pharmaceuticals-inc-nysemktrnn-pioneering-research-in-oncology-19985#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN): Pioneering Research In Oncology"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e5ef7ff4b449e42e0b2e812283dba24e","name":"Fiona Gibson","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f92ca1ce6ecdb59f7bac42afaacd292b.jpeg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f92ca1ce6ecdb59f7bac42afaacd292b.jpeg","caption":"Fiona Gibson"},"description":"Fiona is a finance graduate and an expert in analyzing market trends.","sameAs":["https:\/\/cablemanpro.com\/wallstreetpr","https:\/\/x.com\/@fionahime"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/fiona-gibson"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/19985","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=19985"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/19985\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/13605"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=19985"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=19985"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=19985"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=19985"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}